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Recent evidence has highlighted the role of histamine in inflammation. Since this monoamine has also been strongly implicated in
the pathogenesis of type-1 diabetes, we assessed its effect in the nonobese diabetic (NOD) mouse model. To this end, we used mice
(inactivated) knocked out for the gene encoding histidine decarboxylase, the unique histamine-forming enzyme, backcrossed on
a NOD genetic background. We found that the lack of endogenous histamine in NOD HDC−/− mice decreased the incidence of
diabetes in relation to their wild-type counterpart. Whereas the proportion of regulatory T and myeloid-derived suppressive cells
was similar in both strains, histamine deficiency was associated with increased levels of immature macrophages, as compared
with wild-type NOD mice. Concerning the cytokine pattern, we found a decrease in circulating IL-12 and IFN-𝛾 in HDC−/−
mice, while IL-6 or leptin remained unchanged, suggesting that histamine primarily modulates the inflammatory environment.
Paradoxically, exogenous histamine given to NOD HDC−/− mice provided also protection against T1D. Our study supports the
notion that histamine is involved in the pathogenesis of diabetes, thus providing additional evidence for its role in the regulation
of the immune response.
1. Introduction
Evidence has emerged that inflammatory mechanisms con-
tribute to the onset and progression of type-1 diabetes (T1D).
Recent data further suggest that the initiation of autoimmu-
nity is preceded by inflammation reflected by a proinflamma-
torymetabolic serum profile. Histamine is one of the classical
inflammatory mediators. Many autoimmune diseases are
associatedwith increased histamine levels in serumand tissue
fluids, such as rheumatoid arthritis, Sjo¨gren’s syndrome,
multiple sclerosis, and diabetes mellitus [1–4]. Similarly, it
has been known for many years that histamine is elevated in
tissue biopsies and secretions in the intestine of patients with
Crohn’s disease and ulcerative colitis [5, 6].
During inflammatory responses, histamine, a hydrophilic
vasoactive amine, increases capillary permeability and facil-
itates the immune response by enhancing leukocyte rolling,
adhesion, and vascular extravasation of inflammatory cells to
the site of inflammation. Histamine is recognized not only as
an inflammatory mediator but also as a regulator of immune
responses, including the Th1/Th2 balance and hematopoiesis
[7]. Patients with diabetes are more susceptible to vascular
diseases, which led to the assumption that their increased
circulating histamine levels promoted lipolysis and facilitated
the transport of lipids into tissues. Beside its physiological
role in vascular health, excess histamine, a result of physical
or emotional stress or a chronic disease/inflammatory state,
appears to elicit atherogenic effects [8]. Whether histamine is
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a critical marker or target in the treatment of type-1 diabetes
has not yet been established.
It is still poorly understood how the expression of histi-
dine decarboxylase (HDC), the unique enzyme responsible
for histamine generation, is controlled. HDC is induced
in a variety of tissues in response to bacterial compo-
nents (lipopolysaccharides, peptidoglycan) and to various
cytokines such as IL-1, IL-3, IL-12, TNF, G-CSF, and GM-
CSF. Its upregulation has been associated with pathologi-
cal conditions, including T1D [9]. On the other hand, an
impaired glucose tolerance has been reported in HDC−/−
mice [10], together with autoantibodies reactive to glutamic
acid decarboxylase (GAD).
Histamine exerts important functions in allergy, inflam-
mation, neurotransmission, and the gastrointestinal tract
through G-protein-coupled specific histamine receptors,
termedH1R-H4R. In the context of diabetic physiopathology,
it plays a pivotal role in various physiological functions,
such as feeding behaviour and energy homeostasis. Intrac-
erebroventricular administration of histamine consistently
decreases appetite in several species [11]. Mice with genes
disrupted for HDC are prone to become obese on a high-
fat diet or at advanced age. These metabolic changes pre-
sumably are due to the impaired regulatory loop involving
hypothalamic histamine and H1R [12, 13]. H3Rs located
on histamine neurons negatively regulate the synthesis and
release of histamine. Consequently, treatment with imetit, a
H3R agonist, reduced plasma histamine, leptin, and insulin
levels and has anorexigenic effects in diet-induced obesity
[14].
Histamine has been shown to regulate T cells by enhanc-
ingTh1-type responses through the H1R and downregulating
both theTh1 andTh2 type responses through theH2R [15, 16].
Furthermore, the monoamine is believed to exert immune
regulatory functions inmyeloid cells [17]. It has recently been
described that anti-inflammatory and immunomodulatory
functions of histamine are mediated through the H4R. Thus,
they can be reproduced using the H4R agonist clobenpropit,
which has been shown to suppress IL-12 production, modu-
late dendritic cell migration [18, 19], and regulate the growth
of cancer cells through H4R [20].
Autoimmune diabetes in NOD mice is characterized by
a progressive mononuclear cell infiltration in the pancreatic
islets of NOD mice and leads to beta cell destruction and
hyperglycemia. Pancreas-infiltrating CD4+ and CD8+ T cells
have aTh1 phenotype [21]. It has been recently demonstrated
that leptin can reverse diabetes [22]. Assuming that his-
tamine might be involved in the pathogenesis of diabetes, we
investigated the relationship between endogenous histamine
production and disease development in the NOD mouse
model, using histamine-deficient HDC−/− mice backcrossed
on a NOD background. Here, we show that the lack of
endogenous histamine provides a notable protection against
T1D. We observed an increase of Ly6G+CD11b+ immature
myeloid cells in these mice that was not correlated with
diabetes onset, while IL-12 and IFN-𝛾 levels in the serumwere
decreased, suggesting that endogenous histamine modulates
the inflammatory pattern. Paradoxically, we found that T1D
onset was also delayed when exogenous histamine was given
to NOD. Our study supports a metabolic role of histamine
during the pathogenesis of autoimmune diabetes in accor-
dance with previous findings supporting its immunomodu-
latory functions.
2. Materials and Methods
2.1. Mice. Conventional NODmice (Kd, I-Ag7, and Db) were
bred in our animal facility at the Hoˆpital Necker. HDC−/−
mice generated by Ohtsu et al. [23] received a histamine-
low diet (SAFE (Scientific Animal Food and Engineering))
to avoid exogenous uptake. We generated HDC-deficient
mice by speed backcrossing the HDC-deficient allele against
the NOD background. In order to confirm the allele maps
of NOD diabetes susceptibility genes, we analysed several
representative microsatellite markers: we chose the alleles
related to MHC and numerous insulin-dependent diabetes
genes. The microsatellite analysis confirmed that congenic
mice retained the NOD diabetes susceptibility alleles tested.
Then, mice were intercrossed to generate the HDC−/− mice
used in this study.
2.2. Reagents and Treatments. We purchased histamine and
4-methylhistamine (4-MH) from Sigma-Aldrich and cloben-
propit dihydrobromide (CB) from Tocris. Histamine (4mg/
kg) was injected i.p. in 100𝜇L of saline once a week for 10
weeks starting at 4 weeks of age. H4R agonists, CB (10 𝜇g/kg),
4MH (10 𝜇g/kg), and vehicle (control group for H4R-agonist)
were injected i.p. in 100 𝜇L of saline once a week for 10 weeks.
2.3. Mediators and Histamine Assays. Leptin (Millipore),
IFN-𝛾 (R&D), IL-6 (R&D), and IL-12 (R&D) were quantified
in sera from mice, using ELISA kits according to the manu-
facturer’s instructions. Histamine was quantified by an auto-
mated continuous flow spectrofluorometric technique [24].
2.4. Monitoring for Autoimmune Diabetes and Treatment of
NOD Mice. We treated NOD mice with histamine, CB, or
4-MH and monitored weekly for clinical signs of diabetes
using Gluko-Test reagent sticks, to detect glucose in urine
samples (Boehringer Mannheim, Meylan, France). When
needed, glycemia was also measured in a drop of blood
collected from the tail vein using a Reflolux S glucometer
(Boehringer Mannheim). Incidence of diabetes was defined
based on the discovery, upon serial monitoring, of glycosuria
and hyperglycemia (fasting glycemia >2.5 g/L).
2.5. Adoptive Transfer. To induce T1D by adoptive transfer,
purified CD4+ diabetogenic T cells from prediabetic NOD
mice were injected i.v. into eight-week-old NOD RAG−/−
recipient mice with a CD11b+ population (5 × 106 cells/mice)
magnetically sorted from the bone marrow of HDC+/+ or
HDC−/− mice. Bone marrow cells were stained with CD11b+
MicroBeads (Miltenyi Biotec) then sorted by positive mag-
netic separation on LS columns (MACS Separator, Miltenyi).
The incidence of type-1 diabetes was monitored as described
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above. A high incidence of T1D is elicited within 10 weeks
after T cell transfer.
2.6. Flow Cytometry Analysis. Bone marrow (BM), spleen,
and peripheral whole blood cells were recovered. BM and
spleen cells were prepared as previously reported [25, 26] and
adjusted to a final concentration of 1 × 106 per mL in culture
medium (PBS from GIBCO BRL). Cell suspensions were
stained with the following appropriately labeled antibodies:
CD11b, Ly6G- Ly6C, CD4, CD25, Foxp3, mPDCA-1, CD11c,
CD115, MHC-II, CD80, and CD86 (BD Biosciences, Pont-
de-Claix, France). Samples were acquired on a FACSCanto
II cytometer (BD Biosciences). Mononuclear cells were gated
according to forward- and side-scatter properties and anal-
ysed using the FACS Diva Software.
2.7. Statistical Analysis. Diabetes incidence was plotted using
the Kaplan-Meier method, that is, nonparametric cumulative
survival plot. Statistical comparison between curves was
performed using the log rank (Mantel-Cox) test that provided
the corresponding 𝜒2 values. When needed, statistical com-
parison of mean values was performed using Student’s 𝑡 test.
Differences were considered significant when 𝑃 < 0.05 (∗).
3. Results
3.1. Histamine-Deficient Mice Are Partially Protected against
Type-1 Diabetes. To evaluate the role of histamine in autoim-
mune diabetes, we generated NOD mice deficient for the
gene encoding HDC in the NOD genetic background. These
genetically engineered mice were healthy and heavier than
their wild-type controls after several months. As shown in
Figure 1, the onset of T1D was delayed in NODHDC−/− mice
and the disease incidence remained lower than that among
wild-type controls, suggesting a deleterious role of histamine
during pathogenesis. It may be hypothesized that an increase
in plasma and cellular histamine content contributes to
disease progression by enhancing endothelial permeability,
as suggested for the intimal damage in atherosclerosis [8].
In favour of this hypothesis, histamine levels were effectively
increased in diabetic NOD mice (data not shown), similarly
to what has been reported for streptozotocin-diabetic rats.
3.2. Histamine Levels Affect Circulating IL-12 and IFN-𝛾, but
Not IL-6 or Leptin. To assess potential changes in immuno-
logical and hormonal parameters in the absence of histamine,
we analysed interleukin-12 (IL-12), IL-6, and leptin. IL-12 and
IFN-𝛾 levels were lower in HDC−/− than in NOD mice, but
no differences were noted for IL-6 or leptin (Figure 1(b)).
3.3. The Differentiation of CD11b+Gr-1+ Immature Myeloid
Cells (IMCs) in HDC−/− Mice Is Not Correlated with the
Incidence of Diabetes. As histamine contributes to the
differentiation and maturation of hematopoietic myeloid
cells [27], we performed a comparative cytometry analy-
sis of these populations in histamine-deficient and wild-
type NOD mice in various organs, such as bone mar-
row, spleen, and peripheral blood based on Gr-1, CD11b,
Ly6G, and Ly6C expression by leukocytes. We found an
increased percentage of immature CD11b+Gr-1+ cells in
the peripheral blood and the spleen from NOD HDC−/−
mice (Figure 2(a)). A similar result was observed for the
CD11b+Ly6G+ Ly6C− subset from peripheral blood and
spleen of NOD HDC−/− mice (Figures 2(b) and 2(c)).
These results confirmed the previously reported importance
of histamine for the differentiation of CD11b+Gr-1+ myeloid
subsets in a different genetic background. We hypothesized
that the increased proportion of immature myeloid cells
(IMCs) might be involved in the protection against type-1
diabetes in histamine-deficient mice. To test this assumption,
we performed adoptive transfers of effector CD4+CD62L T
cells together with CD11b+ bone marrow cells from HDC-
deficient or WT mice to NOD RAG−/− recipients, which
did not alter diabetes onset (Figure 2(d)), ruling out the
increase of IMCs as a cause for diabetes progression. We
also analysed the status of myeloid-derived suppressive cells
(MDSCs), which can modulate diabetes onset [28]. However,
no difference was observed when comparing this subset
in both strains (Figure 2(e)). Similarly, the proportion of
CD4+CD25+Foxp3+ regulatory T cells remained unchanged
(Figure 2(f)).
3.4. Exogenous Histamine Protects against T1D. Since the
generation of endogenous histamine appears to enhance
the pathogenesis of T1D, we attempted to reproduce this
deleterious effect by adding exogenous histamine. Wild-type
and NOD HDC−/− mice received i.p. injections of either
vehicle (100 𝜇L PBS) or histamine (4mg/kg), respectively,
once a week for 10 weeks. As shown in Figures 3(a) and
3(b), exogenous histamine not only failed to increase the
incidence of T1D, but also delayed the onset of disease
in both wild-type and HDC−/− mice. We further analysed
whether histamine treatment modulated the expression of
costimulatory molecules on DCs. As shown in Figure 3(c),
decreased expression of class II major histocompatibility
complex (MHC-II) and CD86 molecules occurred only on
pDCs from pancreatic lymph nodes (LNs) in mice treated
with histamine, suggesting that this mediator may modulate
the activation pattern of APCs.
3.5. H4R Agonists Fail to Induce Protection against T1D.
Recent evidence supports the notion that the inflammatory
functions of histamine aremediated through theH4R [20, 29,
30]. For this reason, we examined whether compounds char-
acterized as potent H4R agonists could reproduce the pro-
tective effect provided by exogenous histamine. We injected
NODmice with clobenpropit (CB), an isothiourea derivative
of histamine, or 4MH for 10 weeks and found no significant
protection as compared with mice having received vehicle
alone (Figures 3(d) and 3(e)).
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Figure 1: HDC−/− mice are partially resistant to the development of autoimmune diabetes. (a) Cumulative incidence of spontaneous diabetes
in female HDC+/+ (𝑛 = 22) and HDC−/− strains (𝑛 = 20). Mice were considered diabetic when glycemia >2.5 g/L. (b) Serum levels of IL-6,
IFN𝛾, IL-12, and leptin in HDC−/− NOD and NOD female mice. For measuring leptin, serum was obtained from starved mice. Data are
presented as means ± s.e.m. ∗𝑃 < 0.05, HDC−/− versus HDC+/+ mice determined by Student’s 𝑡-test. (𝑛 = 8).
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Figure 2: HDC deficiency increases CD11b+Gr-1+ and CD11b+Ly6G+ IMCs. (a) The percentages of CD11b+Gr-1+ IMCs in BM, spleen, and
peripheral blood in wild-type and HDC−/− mice were measured by FACS analysis (∗𝑃 < 0.05; mean ± s.d. 𝑛 = 5 for each group). (b) The
relative proportion of CD11b+Ly6G+ cells in bone marrow, peripheral blood and spleen from wild-type and HDC−/− mice measured by FACS
analysis (∗𝑃 < 0.05; mean ± s.d. 𝑛 = 5 for each group). (c)The relative proportion of Ly6G+ Ly6C− cells in bonemarrow, peripheral blood and
spleen of wild-type andHDC−/−micemeasured by FACS analysis (∗𝑃 < 0.05; mean ± s.d. 𝑛 = 5, each group). (d) Bonemarrow-derived IMCs
from HDC−/− do not accelerate diabetes onset. Incidence diabetes was measured in NOD RAG−/− mice after adoptive transfer of pathogenic
lymphocytes and CD11b+ BM-derived IMCs from wild-type mice or HDC−/− mice (𝑛 = 15, ∗𝑃 < 0.05 compared to indicated control).
(e) The percentages of Gr-1+CD115+ MDSCs in spleen and pancreatic LNs in wild-type and HDC−/− mice were measured by FACS analysis
(∗𝑃 < 0.05; mean ± s.d. 𝑛 = 5 for each group). (f) Percentages of CD4+CD25+ Foxp3+ regulatory T cells in spleen and pancreatic LNs in
wild-type and HDC−/− mice were measured by FACS analysis (∗𝑃 < 0.05; mean ± s.d. 𝑛 = 5 for each group).
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Figure 3: Effects of histamine, CB, and 4-MHon diabetes onset in NODmice. (a) Effects of histamine deficiency inHDC−/−mice on diabetes
onset versusWTcontrols. Diabetes prevention inNODHDC−/−mice treatedwith histamine (4mg/kg, i.p. injection, once aweek for 10weeks)
(∗𝑃 < 0.05; 𝑛 = 18, each group). Mice were measured as diabetic when glycemia >2.5 g/L. (b) Similar experiment performed with NOD
HDC+/+ mice (∗𝑃 < 0.05; 𝑛 = 18, each group). (c) Mean fluorescnce intensity of MHCII, CD80, and CD86 molecules on mPDCA1+CD11clow
pDCs (∗𝑃 < 0.05; mean ± s.d., 𝑛 = 5 per group). Effects of CB (d) and 4-MH (e) on diabetes onset in WT mice (𝑛 = 18, each group).
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4. Discussion
In the present study, we provide evidence that histamine
deficiency causes a delay in diabetes onset and decreases its
incidence. This result fits with clinical observations in dia-
betic patients since increased histamine levels were associated
with pathogenesis in these patients [3]. Furthermore, there is
now a compelling body of evidence for the contribution of
histamine to the development of autoimmune diseases from
animal studies [31]. It has also been reported that inhibition of
histamine synthesis in experimental diabetes reduces disease
complication [32]. Several arguments suggest that in the
present study the phenotype results from vascular and/or
metabolic functions of histamine.This conclusion has already
been proposed in a rat diabetic model, since the authors
have shown that the gastric histidine decarboxylase activity
and plasma gastrin levels were increased in connection
with the depletion of insulin [9]. Another argument derives
from the observation that histamine deficiency decreases
atherosclerosis and inflammatory responses [8]. Similar to
our model, lowering the level of endogenous histamine was
protective. We can thus anticipate that decreasing histamine
levels in diabetic patients can decrease the risk of vascular
complications, which is one critical issue in the cure for
patients.
There is increasing evidence that diabetes is under the
control of numerous cytokines and hormones. Since leptin
can influence diabetes [22, 33], we have measured the level
of this mediator in serum of starved mice of both strains.
However, we observed no change in its level. We observed
that IL-12 and IFN-𝛾 levels were lower in NOD HDC−/−
female mice compared with WT controls. These cytokines
are known for promoting diabetes progression in the NOD
strain, possibly via induction of Th1-type cytokines [34, 35].
By contrast, circulating IL-6 or leptin did not differ between
WT and KO mice, ruling out a major involvement of these
factors in the delayed disease onset in HDC-deficient mice.
Even though we detected hematopoietic anomalies in the
myeloid population of HDC−/− mice, these cells were not
involved in the protective response, as demonstrated by adop-
tive transfer. Although neutrophils express the same markers
as IMCs, the protection against diabetes in HDC-deficient
mice cannot be ascribed to an increase of this population
among the CD11b+Gr-1+ subset since neutrophil depletion
has been shown to inhibit type-1 diabetes development in
NOD mice [36]. Furthermore, the expansion of IMCs is not
concomitant with MDSCs since the two populations bear
different markers and most MDSCs do not express Ly6G.
Furthermore, we found that the proportion of regulatory
myeloid cells was not modified comparing both strains.
Finally, the increased histamine levels associated with the
pathogenesis of diabetes are expected to be a consequence
rather than a cause of disease. Therefore, adding exogenous
histamine may act on the gastric mucosa to enhance the
flow of the lipidic factors but will be unable to reverse
the phenotype observed in HDC-deficient mice. Indeed, we
observed the opposite effect.
We describe a new immunomodulatory function of his-
tamine in our model since diabetes onset is delayed in
both wild-type and HDC−/− mice after treatment. It is
plausible that the protective effect ismediated through several
histamine receptors. For example, the role of theH3R on food
intake has been well documented. Since it has been previ-
ously established that H4R drives inflammatory responses
in asthma, dermatitis, arthritis, and colitis [29, 30, 37], we
hypothesized that its agonists could reproduce the effects of
histamine.Thiswas not the case in this study, but even though
we could not validate the H4R pathway using the agonists
CB or 4-MH, we cannot exclude that the dose, the route
of administration, or the choice of the agonists tested was
inadequate. Alternatively, amixture ofH2R andH4R agonists
may be required to obtain a protective effect similar to the one
induced by histamine.
Histamine, which is increased in inflammatory and
pathological situations, has also been shown to decrease, in
vitro, the production of IL-12p70 of monocyte-derived den-
dritic cells (DCs) via H2R and H4R [17, 19, 38] and to inhibit
IL-27 production in activated APCs [39]. The regulation of
cytokine production in maturing DCs causes an alteration of
the T cell polarization that has beenwell described [15, 40, 41].
More recently, it has been reported that histamine decreases
the migration of human pDCs and their cytokine produc-
tion, while increasing regulatory T cell recruitment [42]. In
histamine-treated NOD mice, we observed that pDCs from
pancreatic lymph nodes expressed lower levels of costimula-
tory andMHC-II andCD86molecules than their counterpart
from control mice, consistent with a decreased inflammatory
state. However, the exact mechanisms underlying histamine-
mediated protection deserve further investigation.
Contrary to our anticipations, injection of histamine
did not promote diabetes pathogenesis but, paradoxically,
decreased disease onset.The immunomodulatory function of
histamine has been described in other inflammatory models
[43] and histamine is used therapeutically in patients suf-
fering from acute myeloid leukemia [44]. Histamine release
can be induced by different stimuli, such as cytokines or
microbial stimulation. It has been previously shown that
human basophils release histamine in response to a Toll-
like receptor 2 (TLR2) agonist [45]. Interestingly, TLR2
agonists have also been implicated in the modulation of
T1D in the NOD mouse [46]. Similarly, parasites such as
Schistosoma mansoni protect NOD mice [47] and parasites
stimulate basophils and induce histamine release [48]. These
results support our hypothesis that local histamine release
upon stimulation of immune cells, such as basophils, may
participate in immunoregulatory pathways in autoimmune
diabetes.
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